Navigation Links
Misonix Announces New Distribution Agreement for Belgium and Luxembourg
Date:4/1/2009

devices to their markets. We are particularly pleased that they will be distributing two of our product platforms through their well established channels."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward-looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, li
'/>"/>

SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Misonix Announces New Sales Agency Agreement for Eastern Europe
2. Misonix Announces New Distribution Agreement for Israel
3. Misonix Reports Earnings and Increased Revenues for the Three and Six Months Ended December 31, 2008
4. Misonix Schedules Second Quarter Fiscal Year 2009 Financial Results Conference Call; February 9, 2009 at 4:30 P.M. Eastern
5. Misonix Announces New HIFU Distribution Agreement for Italy
6. Misonix Announces Extension and Expansion of Distribution Agreement With Mentor Corporation
7. Misonix Reports First Quarter Fiscal Year 2009 Financial Results
8. Misonix Schedules First Quarter Fiscal Year 2009 Financial Results Conference Call; November 13, 2008 at 4:30 P.M. Eastern
9. Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study
10. Misonix To Present at The Rodman & Renshaw 10th Annual Healthcare Conference
11. Waters Corporation Announces the Purchase of UPLC/MS Systems by the National Cancer Institute for Advanced Metabolomics Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July ... HIV who was thought to be cured by immediate and ... levels of the AIDS-causing virus in her bloodstream, disappointed federal ... years old, had remained virus-free even though she stopped taking ... hoped her remission would open the door to a functional ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines and segments ... revenue forecast. The well intervention services market in Europe is ... $3.4 billion by 2018, at a CAGR of 7% from ... Europe Well Intervention Market report, to get an idea of ... the segmentation in the Europe well intervention market, and is ...
(Date:7/11/2014)... (HealthDay News) -- Children who have emergency surgery ... and potentially even death than those who have ... However, the Johns Hopkins researchers noted that the ... analyzed data on nearly 440,000 simple emergency surgeries ... a 22-year period. The surgeries are considered ...
(Date:7/11/2014)... According to a new market research ... Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, RFID), Application ... Transportation, Agriculture) & Geography - Global Trends & Forecasts ... Things market was worth $1029.5 Billion in 2013, and ... an estimated CAGR of 4.08% from 2014 to 2020. ...
(Date:7/11/2014)... Researchers from The Miriam Hospital have found that ... significantly higher rates of smoking than those without ... less likely to attempt quitting than those without ... be sufficient for this population. The study and ... print in the American Journal of Public ...
Breaking Medicine News(10 mins):Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Miriam Hospital study examines smoking prevalence 2
... -- The rising prevalence of obesity around the globe ... on healthcare systems and on overall economies. A major ... these burdens to inform public policies. Using a ... consequences from rising obesity rates in the United States ...
... , FRIDAY, Aug. 26 (HealthDay News) -- Scientists ... most common noncancerous tumors in women of childbearing age. ... discomfort, occur in 60 percent of women by the age ... the most common reason for hysterectomy. Despite their importance, ...
... THURSDAY, Aug. 25 (HealthDay News) -- A new scoring system might ... how much time they have left so they can prepare for ... in Palliative Care Study (PiPS) predictor model, the scoring system plugs ... or months a person with advanced cancer most likely has to ...
... People with lower socioeconomic status are much more likely to ... educated, according to a recent UC Davis study. Published online ... that this risk persists even with long-term progress in addressing ... elevated cholesterol. "Being poor or having less than ...
... , THURSDAY, Aug. 25 (HealthDay News) -- One of the ... was the secrecy that shrouded products he was about to ... iPad -- creating tremendous consumer interest. Jobs, announcement Wednesday ... the hugely successful technology company he co-founded in a northern ...
... News) -- The number of obese people in the United States ... 2030, and the number of obese people in the United Kingdom ... predicts. Obesity-related diseases and health care costs will soar as ... The Lancet . Already, the U.S. and U.K. obesity rates ...
Cached Medicine News:Health News:65 million more obese adults in the US and 11 million more in the UK expected by 2030 2Health News:65 million more obese adults in the US and 11 million more in the UK expected by 2030 3Health News:Scoring System May Tell the Dying How Long They Have to Live 2Health News:Lower socioeconomic status linked with heart disease despite improvements in other risk factor 2Health News:Steve Jobs Faces Uphill Battle Against Cancer: Experts 2Health News:Steve Jobs Faces Uphill Battle Against Cancer: Experts 3Health News:Obesity Continues to Balloon in U.S. and U.K.: Study 2
(Date:7/10/2014)... 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... analog IC solutions, today announced that it will host ... at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) ... 2014 third quarter ended June 30, 2014. ... before 6:50 a.m. Pacific time on July 24, 2014.  ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
(Date:1/15/2014)... 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced ... 2013, compared to sales of $2,202,000 for the prior year ... quarter has also shown growth over the preceding quarter,s sales, ... this fiscal year. Markets that experienced sales increases over the ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... REGN ) today announced results from the Phase ... Trap) for the second-line treatment of non-small cell lung ... the chemotherapy drug docetaxel did not meet the pre-specified ...
... Nephros, Inc. (OTC Bulletin Board: NEPH ), ... for therapeutic applications, infection control, and water purification, today ... placement that together resulted in gross proceeds of approximately ... by Nephros from the rights offering and private placement ...
Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 2Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 3Nephros Announces Completion of $3.2 Million Financing Through Rights Offering and Private Placement Transactions 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: